{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:14:25Z","timestamp":1780100065492,"version":"3.54.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["K08HL140175"],"award-info":[{"award-number":["K08HL140175"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.phrs.2025.108062","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:23:40Z","timestamp":1765239820000},"page":"108062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pharmacological profile and therapeutic evaluation of ROC-101, a potent and selective ROCK inhibitor, in arterial hypertension and pulmonary fibrosis"],"prefix":"10.1016","volume":"223","author":[{"given":"Rigen","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jiang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Skucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-In","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Kolahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian J.","family":"Spinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel S.","family":"Knipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeegar P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Kathryn","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serra","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn N.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3024-778X","authenticated-orcid":false,"given":"Masha V.","family":"Poyurovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.108062_bib1","doi-asserted-by":"crossref","DOI":"10.4161\/sgtp.29846","article-title":"Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions","volume":"5","author":"Julian","year":"2014","journal-title":"Small GTPases"},{"issue":"8","key":"10.1016\/j.phrs.2025.108062_bib2","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/j.1460-2075.1996.tb00539.x","article-title":"The small GTP-binding protein Rho binds to and activates a 160 kDa Ser\/Thr protein kinase homologous to myotonic dystrophy kinase","volume":"15","author":"Ishizaki","year":"1996","journal-title":"EMBO J."},{"issue":"49","key":"10.1016\/j.phrs.2025.108062_bib3","doi-asserted-by":"crossref","first-page":"29051","DOI":"10.1074\/jbc.270.49.29051","article-title":"A novel serine\/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes","volume":"270","author":"Leung","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.phrs.2025.108062_bib4","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1002\/j.1460-2075.1996.tb00574.x","article-title":"Rho-associated kinase, a novel serine\/threonine kinase, as a putative target for small GTP binding protein Rho","volume":"15","author":"Matsui","year":"1996","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.phrs.2025.108062_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00018-009-0189-x","article-title":"Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity","volume":"67","author":"Hahmann","year":"2010","journal-title":"Cell Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.phrs.2025.108062_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-5793(96)00811-3","article-title":"ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine\/threonine kinase in mice","volume":"392","author":"Nakagawa","year":"1996","journal-title":"FEBS Lett."},{"issue":"5272","key":"10.1016\/j.phrs.2025.108062_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.273.5272.245","article-title":"Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)","volume":"273","author":"Kimura","year":"1996","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.phrs.2025.108062_bib8","doi-asserted-by":"crossref","first-page":"12257","DOI":"10.1074\/jbc.272.19.12257","article-title":"Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation","volume":"272","author":"Kureishi","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2025.108062_bib9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1083\/jcb.140.3.647","article-title":"Rho-kinase phosphorylates COOH-terminal threonines of ezrin\/radixin\/moesin (ERM) proteins and regulates their head-to-tail association","volume":"140","author":"Matsui","year":"1998","journal-title":"J. Cell Biol."},{"issue":"5","key":"10.1016\/j.phrs.2025.108062_bib10","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1074\/jbc.275.5.3577","article-title":"Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop","volume":"275","author":"Ohashi","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2025.108062_bib11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1074\/jbc.M007074200","article-title":"Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase","volume":"276","author":"Sumi","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2025.108062_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrm2890","article-title":"Linking actin dynamics and gene transcription to drive cellular motile functions","volume":"11","author":"Olson","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108062_bib13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1172\/JCI66700","article-title":"Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis","volume":"123","author":"Zhou","year":"2013","journal-title":"J. Clin. InvestIG."},{"issue":"7","key":"10.1016\/j.phrs.2025.108062_bib14","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1039\/C5IB90025E","article-title":"Between a rock and a soft place: recent progress in understanding matrix mechanics","volume":"7","author":"Moraes","year":"2015","journal-title":"Integr. Biol. (Camb. )"},{"issue":"1","key":"10.1016\/j.phrs.2025.108062_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11926-018-0710-z","article-title":"Matrix stiffness: the conductor of organ fibrosis","volume":"20","author":"Santos","year":"2018","journal-title":"Curr. Rheuma Rep."},{"issue":"5","key":"10.1016\/j.phrs.2025.108062_bib16","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1046\/j.1523-1755.2002.00328.x","article-title":"Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction","volume":"61","author":"Nagatoya","year":"2002","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.phrs.2025.108062_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1164\/ajrccm.163.1.2001089","article-title":"Contribution of small GTPase Rho and its target protein rock in a murine model of lung fibrosis","volume":"163","author":"Shimizu","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med"},{"issue":"1","key":"10.1016\/j.phrs.2025.108062_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1183\/09031936.00060708","article-title":"MMP expression and abnormal lung permeability are important determinants of outcome in IPF","volume":"33","author":"McKeown","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.phrs.2025.108062_bib19","doi-asserted-by":"crossref","first-page":"C195","DOI":"10.1152\/ajpcell.2000.279.1.C195","article-title":"ROCK mediates thrombin's endothelial barrier dysfunction","volume":"279","author":"Carbajal","year":"2000","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108062_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.trecan.2022.12.001","article-title":"Preclinical to clinical utility of ROCK inhibitors in cancer","volume":"9","author":"Barcelo","year":"2023","journal-title":"Trends Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2025.108062_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/fca.11.51","article-title":"Rho kinase as a therapeutic target in cardiovascular disease","volume":"7","author":"Surma","year":"2011","journal-title":"Future Cardiol."},{"key":"10.1016\/j.phrs.2025.108062_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/DDDT.S435522","article-title":"The role of Rho kinase inhibitors in corneal diseases","volume":"18","author":"Futterknecht","year":"2024","journal-title":"Drug Des. Devel Ther."},{"issue":"153","key":"10.1016\/j.phrs.2025.108062_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0021-2019","article-title":"The therapy of idiopathic pulmonary fibrosis: what is next?","volume":"28","author":"Somogyi","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.phrs.2025.108062_bib24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fphar.2015.00276","article-title":"The function of Rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease","volume":"6","author":"Hartmann","year":"2015","journal-title":"Front Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2025.108062_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/FJC.0b013e31802df112","article-title":"Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats","volume":"49","author":"Jiang","year":"2007","journal-title":"J. Cardiovasc Pharm."},{"issue":"8","key":"10.1016\/j.phrs.2025.108062_bib26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/hr.2015.33","article-title":"Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension","volume":"38","author":"Jiang","year":"2015","journal-title":"Hypertens. Res"},{"key":"10.1016\/j.phrs.2025.108062_bib27","article-title":"Rho-kinase 1\/2 inhibition prevents transforming growth factor-beta-induced effects on pulmonary remodeling and repair","volume":"11","author":"Wu","year":"2020","journal-title":"Front Pharm."},{"issue":"10","key":"10.1016\/j.phrs.2025.108062_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271281","article-title":"Sex differences in a murine model of asthma are time and tissue compartment dependent","volume":"18","author":"Chiarella","year":"2023","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.phrs.2025.108062_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019488","article-title":"Penetrance of severe pulmonary arterial hypertension in response to vascular endothelial growth factor 2 blockade in a genetically prone rat model is reduced by female sex","volume":"10","author":"Chaudhary","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"D1","key":"10.1016\/j.phrs.2025.108062_bib30","doi-asserted-by":"crossref","first-page":"D1438","DOI":"10.1093\/nar\/gkad944","article-title":"The IUPHAR\/BPS Guide to PHARMACOLOGY in 2024","volume":"52","author":"Harding","year":"2024","journal-title":"Nucl. Acids Res."},{"issue":"11","key":"10.1016\/j.phrs.2025.108062_bib31","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1474-4422(24)00373-9","article-title":"Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"23","author":"Koch","year":"2024","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108062_bib32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/CIRCRESAHA.107.149047","article-title":"Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling","volume":"101","author":"Oka","year":"2007","journal-title":"Circ. Res."},{"issue":"9","key":"10.1016\/j.phrs.2025.108062_bib33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2176\/nmc.46.421","article-title":"Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage","volume":"46","author":"Zhao","year":"2006","journal-title":"Neurol. Med Chir. (Tokyo"},{"issue":"2","key":"10.1016\/j.phrs.2025.108062_bib34","doi-asserted-by":"crossref","first-page":"H243","DOI":"10.1152\/ajpheart.00728.2013","article-title":"Temporal hemodynamic and histological progression in Sugen5416\/hypoxia\/normoxia-exposed pulmonary arterial hypertensive rats","volume":"306","author":"Toba","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1-2","key":"10.1016\/j.phrs.2025.108062_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J. Ocul. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2025.108062_bib36","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2012.06.037","article-title":"Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.phrs.2025.108062_bib37","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.00350.2015","article-title":"\u03b1-Smooth muscle actin is an inconsistent marker of fibroblasts responsible for force-dependent TGF\u03b2 activation or collagen production across multiple models of organ fibrosis","volume":"310","author":"Sun","year":"2016","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108062_bib38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1254\/jphs.92.56","article-title":"Inhibition of high K+-induced contraction by the ROCKs inhibitor Y-27632 in vascular smooth muscle: possible involvement of ROCKs in a signal transduction pathway","volume":"92","author":"Sakamoto","year":"2003","journal-title":"J. Pharm. Sci."},{"issue":"21","key":"10.1016\/j.phrs.2025.108062_bib39","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1021\/jm800986w","article-title":"Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors","volume":"51","author":"Feng","year":"2008","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2025.108062_bib40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.diff.2013.07.004","article-title":"From tissue mechanics to transcription factors","volume":"86","author":"Janmey","year":"2013","journal-title":"Differentiation"},{"issue":"1","key":"10.1016\/j.phrs.2025.108062_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1124\/jpet.106.110635","article-title":"Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities","volume":"320","author":"Doe","year":"2007","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2025.108062_bib42","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/HYPERTENSIONAHA.109.134353","article-title":"Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor","volume":"54","author":"L\u00f6hn","year":"2009","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.phrs.2025.108062_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11906-001-0028-4","article-title":"RhoA\/Rho-kinase, vascular changes, and hypertension","volume":"3","author":"Chitaley","year":"2001","journal-title":"Curr. Hypertens. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2025.108062_bib44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1183\/09031936.06.00025506","article-title":"Regulation of airway smooth muscle RhoA\/ROCK activities by cholinergic and bronchodilator stimuli","volume":"28","author":"Liu","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.phrs.2025.108062_bib45","article-title":"CCN1 expression by fibroblasts is required for bleomycin-induced skin fibrosis","volume":"3","author":"Quesnel","year":"2019","journal-title":"Matrix Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108062_bib46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1124\/pr.114.009381","article-title":"The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis","volume":"67","author":"Knipe","year":"2015","journal-title":"Pharm. Rev."},{"issue":"3","key":"10.1016\/j.phrs.2025.108062_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/13543776.2014.863279","article-title":"Rho kinase inhibitors: a patent review (2012-2013)","volume":"24","author":"Feng","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"issue":"3","key":"10.1016\/j.phrs.2025.108062_bib48","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/01.RES.0000201960.04223.3c","article-title":"Rho kinases in cardiovascular physiology and pathophysiology","volume":"98","author":"Loirand","year":"2006","journal-title":"Circ. Res"},{"issue":"4","key":"10.1016\/j.phrs.2025.108062_bib49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1165\/rcmb.2017-0075OC","article-title":"The Rho kinase isoforms ROCK1 and ROCK2 each contribute to the development of experimental pulmonary fibrosis","volume":"58","author":"Knipe","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108062_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1160\/TH09-06-0403","article-title":"Driving Rho GTPase activity in endothelial cells regulates barrier integrity","volume":"103","author":"Beckers","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.phrs.2025.108062_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12127","article-title":"Clinical significance of pulmonary hypertension in interstitial lung disease: a consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-group 3 pulmonary hypertension","volume":"12","author":"Nikkho","year":"2022","journal-title":"Pulm. Circ."},{"issue":"1-a","key":"10.1016\/j.phrs.2025.108062_bib52","first-page":"S2","article-title":"Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: the latest advances in diagnosis and treatment","volume":"31","author":"Nathan","year":"2025","journal-title":"J. Manag Care Spec. Pharm."},{"issue":"23","key":"10.1016\/j.phrs.2025.108062_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252312858","article-title":"Searching for old and new small-molecule protein kinase inhibitors as effective treatments in pulmonary hypertension-a systematic review","volume":"25","author":"Jasi\u0144ska-Stroschein","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2025.108062_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40256-023-00613-5","article-title":"A systematic review of novel therapies of pulmonary arterial hypertension","volume":"24","author":"Nabeh","year":"2024","journal-title":"Am. J. Cardiovasc Drugs"},{"issue":"2","key":"10.1016\/j.phrs.2025.108062_bib55","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00380-009-1176-8","article-title":"Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension","volume":"25","author":"Fujita","year":"2010","journal-title":"Heart Vessels"},{"issue":"1","key":"10.1016\/j.phrs.2025.108062_bib56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijcard.2014.09.101","article-title":"Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study","volume":"177","author":"Jiang","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108062_bib57","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/chd.12764","article-title":"The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension","volume":"14","author":"Ruan","year":"2019","journal-title":"Congenit. Heart Dis."},{"issue":"10","key":"10.1016\/j.phrs.2025.108062_bib58","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1253\/circj.CJ-13-0443","article-title":"Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension","volume":"77","author":"Fukumoto","year":"2013","journal-title":"Circ. J."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:39:29Z","timestamp":1773887969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":58,"alternative-id":["S1043661825004876"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108062","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological profile and therapeutic evaluation of ROC-101, a potent and selective ROCK inhibitor, in arterial hypertension and pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108062"}}